Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$15.0M | -$11.9M | -$6.66M | -$4.96M | -$6.45M | -$32.9M | -$80.0M | -$106M | -$141M | -$95.4M |
| Net income | -$14.8M | -$11.9M | -$6.56M | -$4.63M | -$6.33M | -$32.4M | -$76.2M | -$97.2M | -$24.3M | -$91.0M |
| EPS (diluted) | -$2.28 | -$1.82 | -$0.61 | -$0.27 | -$0.24 | -$0.82 | -$1.90 | -$2.32 | -$1.46 | -$1.88 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.2M | -$8.24M | -$4.77M | -$2.51M | -$5.38M | -$30.2M | -$77.5M | -$82.0M | -$117M | -$32.3M |
| Capital expenditures | $75.0K | — | — | $18.0K | — | $22.2M | $2.71M | $414K | $103K | $581K |
| Free cash flow | -$12.3M | — | — | -$2.53M | — | -$52.4M | -$80.2M | -$82.4M | -$117M | -$32.8M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.6M | $10.5M | $19.8M | $23.1M | $93.5M | $233M | $201M | $121M | $129M | $95.5M |
| Total assets | $19.3M | $10.8M | $20.1M | $23.5M | $94.3M | $267M | $235M | $152M | $158M | $118M |
| Total liabilities | $665K | $1.13M | $511K | $1.39M | $2.10M | $12.9M | $7.29M | $14.2M | $11.8M | $44.0M |
| Shareholders' equity | $18.6M | $9.70M | $19.6M | $22.1M | $92.2M | $254M | $228M | $137M | $146M | $74.4M |
| Retained earnings | -$145M | -$157M | -$164M | -$169M | -$175M | -$207M | -$284M | -$381M | -$405M | -$496M |
| Shares (wtd avg diluted) | 6.59M | 6.60M | 17.2M | 21.8M | 35.2M | 39.4M | 40.2M | 41.9M | 46.6M | 48.3M |
Every figure is extracted from FILANA THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.